EnglishThe aim of the present study was to analyze the prognostic role of combined PET and BCL2/IGH analysis, performed at the EOT, in a subset study of the phase III trial FOLL05 (NCT00774826), in which patients with FL were randomized to R-CVP (rituximab plus cyclophosphamide, vincristine and prednisone), R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone) or R-FM (rituximab plus fludarabine and mitoxantrone).6 This study was conducted in compliance with the Declaration of Helsinki, was approved by the appropriate research ethics committee, and required each patient to provide written informed consent.
| Data di pubblicazione: | 2016 |
| Titolo: | Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi |
| Autori: | Luminari, Stefano; Galimberti, Sara; Versari, Annibale; Biasoli, Irene; Anastasia, Antonella; Rusconi, Chiara; Ferrari, Angela; Petrini, Mario; Manni, Martina; Federico, Massimo |
| Autori: | |
| Digital Object Identifier (DOI): | 10.3324/haematol.2015.132811 |
| Rivista: | |
| Volume: | 101 |
| Pagina iniziale: | 66 |
| Pagina finale: | 68 |
| URL: | http://www.haematologica.org/content/101/2/e66 |
| Appare nelle tipologie: | Articolo su rivista |
File in questo prodotto:
| File | Descrizione | Tipologia | Licenza | |
|---|---|---|---|---|
| 422 (ex757).pdf | Versione editoriale | Open Access Visualizza/Apri |
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
Copyright © 2019